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FEV1 or 6-minute walk values after LVRS. By using the
algorithm depicted in Figure 2, patients can be well selected
for LVRS to possibly reset the baseline of their pulmonary
function to their peak after transplantation. This reestablish-
ment of baseline lung function has been demonstrated by
improved 6-minute walk values, oxygen requirements,
room air saturations at rest, and FEV1.
Given the less-than-optimal reports of both wedge resec-
tions and traditional LVRS in the SLT literature, anatomic
resections were chosen in an effort to facilitate pulmonary
healing. This strategy appears to have been successful, but
prolonged air leak still occurred in half of the patients and sig-
nificantly extended hospital stays. The extended hospital
stays and incidence of complications demonstrate the level
of care needed for these patients. Although intense pulmo-
nary rehabilitation was required for recovery from their
lung resections, 7 of 8 patients discharged from the hospital
saw improved pulmonary function, as demonstrated by their
improved FEV1. In terms of late follow-up, 7 of 8 hospital
survivors are alive at a mean of 20 months after LVRS.
These data demonstrate that LVRS by means of formal
anatomic resection in patients undergoing SLT with signifi-
cant graft compression from NLH is feasible. Although
hospital stay and pulmonary rehabilitation can be intensive,
improvements in lung function can be accomplished in nearly
all properly selected patients, with excellent long-term sur-
vival. In conclusion, LVRS should be considered in patients
with decreasing graft function caused by graft compression
from NLH.
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Discussion
Dr Patricia Thistlethwaite (San Diego, Calif). I would like to con-
gratulate Dr Reece and his colleagues at the University of Colorado
for an excellent presentation and a well-written article. This is
indeed a difficult set of patients to manage, those with overinflation
of a native lung compromising transplant allograft function. It is nice
to see that your surgical approach, first described by our group at the
University of California at San Diego in 1996 in the SLT patient
population with emphysema, is still being effectively used to this
day. I think many of us would agree that LVRS after lung transplan-
tation is performed as a last resort, when allograft deterioration
occurs and the CT scan shows compression of the transplant lung.
This is reflected by the high-risk stakes of doing this operation
seen by the fact that you had a 20% perioperative mortality and
that most patients had long intensive care unit and hospital stays. I
am surprised that you chose thoracotomy over thoracoscopy in
this immunocompromised and pulmonary compromised set of pa-
tients. Newer technologies, such as the use of 1-way endobronchial
valves and the trend of performing double-lung transplantations in
patients with COPD and a1-antitrypsin disease, might eliminate
the need for LVRS in these subsets of patients who have transplan-
tations in the future. I have several questions.
First, most cases of SLT for emphysema show some degree of
hyperinflation of the native lung from the beginning with the first
postoperative chest radiograph. What is your threshold for surgical
intervention, and are there specific CT scan measurements of medi-
astinal shift that you could retrospectively identify as being useful to
determine who would benefit from this operation and when inter-
vention should occur?
Dr Reece.We have not applied any kind of volumetric analysis
at this point. We have not been able to apply the technology, and our
patients do not generally get a CT scan repeatedly unless there is
a problem. Chest radiography is the way that we most commonly
follow them, and unfortunately, the CT scans that we order are usu-
ally because of another problem, such as infection or concern about
bronchiolitis; therefore it has been hard to define any CT criteria
alone that would push us to do an LVRS.
Dr Thistlethwaite. Thank you. Most of your patients underwent
LVRS in a time frame when chronic rejection is common. When do
you decide that symptoms are due to allograft compression rather
than rejection? We know that there is no reliable CT scan finding
that is pathognomonic for chronic rejection. There is also well-docu-
mented sampling error and pathologic grading variability in the di-
agnosis of chronic rejection that might obscure why these patients
have progressive shortness of breath. Were they empirically treated
for chronic rejection before LVRS? (end cassette side)
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Dr Reece.. from reviewing their charts. None of these patients
were treated preoperatively. We hope that our algorithm rules out
the majority of the patients who are having chronic rejection or hav-
ing other problems besides NLH. As shown by one of our 2 deaths,
we actually missed it in that patient. I think it is a difficult call to
make, but given all of the clinical information, we have been able
thus far to make a good judgment of who has bronchiolitis and
who does not. It is definitely a problem that we have seen clinically
and something that we try to avoid and have not been able to elim-
inate completely.
Dr Thistlethwaite. Yes, in our group it seems to almost always
be a concurrent problem.
Finally, and probably most importantly, in your cohort of
patients, did LVRS result in permanent relief from NLH, or was it
temporary? If so, for how long?
Dr Reece. It looks like the patients take around 6 months or so to
recover to a peak after their LVRS, but they do have some gradual de-
crease thatwe see in all of the patients undergoing lung transplantation.
We do think thatwe reset their baseline, but it is not a cure-all for future
deterioration. It seems to be something that can reset their baseline and
allow them toget back to a pointwhere they are feelinggood anddoing
the things that they need to and continue along with their lives.
Dr Thistlethwaite. Thank you very much, and I would like to
thank the Association for the privilege of the floor.
Dr Michael Mulligan (Seattle, Wash). I applaud your desire to
weigh in with this population. This is a topic that has been discussed
by revered colleagues who have condemned it as being fairly useless
and inappropriate. Your data are very encouraging, even though the
mortality and morbidity appear to be quite high. My question to you
is this:Who pays for this? The overwhelming majority of payers will
not reimburse unilateral LVRS, yet you are here telling us that this is
indeed LVRS. A bullectomy can be reimbursed as a unilateral proce-
dure, but for patients about whom we have made ongoing solicita-
tions to try and get reimbursement, we have been shut down. Who
is paying for it, and how are you coding it to get it paid for?
Dr Reece. I am not certain about that. I have no idea about the
coding or reimbursement at this point, but I will look into it and
get back to you.
Dr Robert Cerfolio (Birmingham, Ala). We are coding it as bul-
lectomy. That is a very important point. That is how we list it, and
that iswhat I think it really is, notLVRS.Wehave done several of these
at Birmingham, and I want you to takeme on your cognitive leap from
doing a large wedge resection to doing a lobectomy. I think one of the
deaths was from a bronchopulmonary fistula, which you could have
avoided. Second, yourmain problemwas prolonged air leaks.Nomat-
ter whether you do a fissureless lobectomy like most of us do, where
one staples the fissure last and takes all of the vessels and bronchus
first, or not, it is the large space that helps prevent sealing of the leaks.
There is a lack of parietal to visceral pleural apposition. Therefore why
perform an anatomic operation for a problem that does not require one
and leads to a larger space deficit?Why not do a wedge resection, like
we do in bullectomy surgery or in LVRS? Thus I have done all these
with LVRS-type techniques, using pericardially buttressed staple
lines, pleural tents, and justwedges. Iwouldnot do a lobectomy,where
a stump is at risk, especially in an immunocompromised patient.
Therefore tell me again why I should follow your cognitive leap of do-
ing a lobectomy instead of just a large wedge resection.
Dr Reece. I think there are some data, although I would have to
acknowledge that they are few, that patients with lung transplanta-
tions who get wedge resections—which LVRS is going to be an
extended wedge resection—do worse. I mean, there is nothing to
validate that, but we believe that if we have a small staple line of
a bronchus and hopefully a smaller one of less tissue within the
fissure itself, we would decrease the amount of air leaks from the
lung parenchyma itself.
Dr Ross Bremner (Phoenix, Ariz). Most of your patients, or all
of your patients, have chronic problems. I wonder with your expe-
rience nowwhat your guidelines are for doing this in an acute setting
in which you get one lung only offered, and when the lung comes to
you, it is a little smaller than you had hoped for, or in the setting in
which in the first couple of days after the operation you are having
a lot of trouble with NLH on the vent.
Dr Reece.We have actually published on NLH in the acute set-
ting, and with thoughtful management, we were able to get beyond
this, so that it does not cause an increase in mortality and it does not
cause an increase in morbidity, but I think this is a completely dif-
ferent subject from the chronic NLH that we are dealing with
here. There are reports in the literature of surgeons doing bullecto-
mies or lobectomies at the same time that they are doing the opposite
lung transplantation, but that would subject many patients to a super-
fluous procedure for a process that would be unlikely to lead to an
eventual compromise in pulmonary function. In our opinion, the
low incidence of significant NLH does not justify prophylactic con-
tralateral resection.
Dr RichardWhyte (Stanford, Calif). I enjoyed your article, and
I think it is very nice to have some data on what happens with these
patients because many of us who have been involved with lung
transplantations have been asked to do this operation in patients
over the years, and now we kind of know what happens. Interest-
ingly, you can use the results to justify whichever approach, whether
you want to do it or not.
My question relates to how you exclude bronchiolitis obliterans,
which is actually a diagnosis of exclusion itself, yet you seem to be
able to eradicate or eliminate those that you think have bronchiolitis
obliterans. In fact, with your deaths, you had a 50% error rate. How
do you eliminate a diagnosis of exclusion?
Dr Reece. That is a good question. I would have to lean on our
pulmonary colleagues, as well as the pathologists, and all come to-
gether with a conclusion of whether we all believe that they have
bronchiolitis. I do not know whether I can quantify how we say
they do not at this point, but we have been fairly lucky and success-
ful in avoiding it in all but 1 patient.
Dr Thistlethwaite. Dr Reece, I have one last question. Do
you have a similar cohort of patients in whom you have actually
chosen to do a contralateral retransplantation instead of lung re-
duction? Do you have any comparisons between the 2 groups? If
one looks at this, all of these patients would likely be candidates
for retransplantation of the contralateral native lung, and when
you see the morbidity and mortality of LVRS, one could argue
that the morbidity and mortality of retransplantation would po-
tentially be less, with potentially more benefit. Have you tried
that, and do you have any comparison data to tell us about?
Dr Reece. I have not looked at that, but that would definitely be
something I would like to look at in the future.
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